Trial Profile
Efficacy and tolerability of BMS 650032 + peginterferon alfa-2a + ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2012
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 04 Apr 2012 Results will be presented at EASL-2012 according to a Bristol-Myers Squibb media release.
- 04 Apr 2011 New trial record
- 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.